It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).... Jun 24
Shorter infusion time will further improve the twice-yearly treatment experience for OCREVUS, the only B-cell therapy for relapsing and primary progressive MS with ... Dec 15
Cipla Limited today announced that it has received final approval for its ANDA for Dimethyl Fumarate Capsules... Sep 25
-Advertisements-